PBMs not only manage a company's drug plan, they also negotiate directly with pharmacies and drug manufacturers, creating conflicts of interest. In addition to being paid by the company to manage their plan, the PBM also profits from the gap it creates between what a company is willing to pay for a prescription and what the pharmacy is willing to accept. The PBM's goal of getting the best deal possible for the company it represents directly conflicts with its desire to create an added profit stream from the margin it creates.
These various revenue streams are lucrative and PBMs have seen profits soar. But rather than these profits encouraging increased market entry and competition, the industry is consolidating, as evidenced by the announced merger of the two largest and most profitable PBMs -- Express Scripts and Medco. If the Federal Trade Commission (FTC) approves this merger, the merged company will manage the pharmacy plans of roughly 120 million Americans. This will further increase the already highly concentrated PBM industry, as well as further increasing profits and leading to anti-competitive risks.
In much the same way that Kudzu was brought in to solve a problem yet created a crisis, PBMs were brought in to control costs but have gained excessive market power, thereby posing anti-competitive risks and higher prices for consumers. Oversight needs to review the industry's market power, self-dealing, conflicts of interest and lack of transparency - all of which will be exacerbated if the FTC does not block the planned merger.
Steve Pociask is the president of The American Consumer Institute Center for Citizen Research. The Institute is a nonprofit educational and research institute.